ClinicalTrials.gg
CompletedNCT04112784Updated Oct 6, 2022Results posted

Desaturation Validation of INVSENSOR00039

An interventional study of INVSENSOR00039 in Healthy, sponsored by Masimo Corporation. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-06.

Sponsored by Masimo Corporation (part of Danaher Corporation) · Interventional and Other

Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study is designed to compare the accuracy of a noninvasive measurement of oxygen saturation compared to reference values obtained by a laboratory blood gas analyzer. Arterial blood samples will be collected from healthy adult subjects while undergoing a desaturation procedure wherein the concentration of oxygen inhaled is slowly reduced. The subject will then be returned to breathing room air.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Masimo Corporation is the lead sponsor of 105 studies on the registry; 1 is open to participants now.

Of its 79 completed or terminated interventional studies of FDA-regulated products, 66 (84%) have results posted.

First submitted before Masimo Corporation became part of Danaher Corporation.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria

  • Subject is 18-50 years of age.
  • Subject weighs a minimum of 110 lbs and no more than 250 lbs unless subject is over 6 feet tall.
  • Hemoglobin value is greater than or equal to 11 g/dL.
  • Baseline heart rate ≥ 45 bpm and ≤ 85 bpm.
  • Carbon monoxide (CO value) ≤ 2.0% fraction of carboxyhemoglobin (FCOHb)
  • Subject has a physical status of ASA I or II (American Society of Anesthesiology Class I; Healthy subjects without any systemic disease at all. American Society of Anesthesiology Class II; subjects with mild systemic disease) as it applies to the systemic disease portion of the classification.
  • Blood pressure: Systolic Blood Pressure ≤ 140 mmHg and ≥ 90 mmHg, Diastolic Blood Pressure ≤ 90 mmHg and ≥ 50 mmHg, and if blood pressure is lower than 100/60 subject passes an orthostatic blood pressure test.
  • Subject is able to read and communicate in English and understands the study and risks involved.

Exclusion Criteria (* = per physician discretion)

  • Subject is pregnant.
  • Subject has a Body Mass Index (BMI) > 35 and has been classified as morbidly obese or at an increased risk for participation by a medical professional.
  • Subject has a history of fainting (vasovagal), blacking out or losing consciousness during or after blood draw, or has a fear of blood draws.
  • Subject smokes one pack of cigarettes or more in one week, and/or the equivalent of e- cigarette liquid, and smokers are not being recruited as indicated in the Case Study Report Form (CSRF).
  • Subject has open wounds, inflamed tattoos or piercings, and/or any visible healing wounds that a medical professional renders them at an increased risk for participation.*
  • Subject has known drug or alcohol abuse and/or use of recreational drugs.
  • Subject experiences frequent or severe headaches and/or migraine headaches, migraine auras, altitude sickness, and/or headaches accompanied by visual changes or sensitivity to light or sound.
  • Subject has experienced a concussion or head injury with loss of consciousness within the last 12 months.
  • Subject has any history of a stroke, myocardial infarction, seizures or heart attack.
  • Subject has a chronic bleeding disorder (i.e. hemophilia).
  • Subject who has taken anticoagulant medication within the last 30 days (excluding nonsteroidal anti-inflammatory drugs (NSAIDS)).
  • Subject has donated blood within the past 4 weeks.
  • Subject has Wolff-Parkinson-White Syndrome or Stokes-Adams Syndrome.
  • Subject has any symptomatic cardiac dysrhythmia (i.e. atrial fibrillation) and has not received clearance by their physician to participate.
  • Subject has a known neurological and/or psychiatric disorder (i.e. schizophrenia, bipolar disorder, Multiple Sclerosis, Huntington's Disease) that interferes with the subject's level of consciousness.
  • Subject has taken opioid pain medication 24 hours before the study.
  • Subject has any type of infectious disease (i.e. Hepatitis, HIV, Tuberculosis, Flu, Malaria, Measles, etc.).
  • Subject is taking medications known to treat any type of infectious disease.*
  • Subject has either signs or history of peripheral ischemia or carpal tunnel syndrome.
  • Subject has had invasive surgery within the past year- including but not limited to major dental surgery*, appendix*, plastic surgery*.
  • Subject has had invasive surgery within the past year- including but not limited to gallbladder, major fracture repairs (involving plates/ screws), jaw surgery, urinary tract surgery, major ears, nose, and throat (ENT) surgery, joint replacement or gynecological surgeries, heart surgery or thoracic surgery.
  • Subject has symptoms of congestion, head cold, flu or other illnesses.
  • Subject experiences claustrophobia or has generalized anxiety disorder.
  • Subject has been in severe car accident(s) or a similar type of accident(s) requiring hospitalization within the last 12 months.
  • Subject has any cancer or history of cancer (not including skin cancer).*
  • Subject has chronic unresolved asthma, lung disease (including chronic obstructive pulmonary disease (COPD)) or respiratory disease.
  • Subject is allergic to lidocaine, latex, adhesives, or plastic.
  • Subject has heart conditions, insulin-dependent Diabetes or uncontrolled hypertension.
  • Subject has delivered vaginally, has had a pregnancy terminated, a miscarriage with hospitalization, or had a C-section within the last 6 months.
  • Subject intends on participating in any heavy lifting, repetitive movement of their wrist (including riding a motorcycle, tennis) or exercise (working out, riding a bike, riding a skate board etc.), or any activity that will put additional stress on the wrist within 24 hours following a study that involves an arterial line.
  • Subject has any medical condition which in the judgment of the investigator and/or medical staff, renders them ineligible for participation in this study or subject is deemed ineligible by the discretion of the investigator/study staff.
05

Study design

Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    INVSENSOR00039

    All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00039 sensor.

    Device: INVSENSOR00039

Interventions

  • DeviceINVSENSOR00039

    Noninvasive pulse oximeter sensor

06

What researchers measure

Primary outcomes

  1. Oxygen Saturation (SpO2) Accuracy of Sensor

    Performance of the sensors will be determined by comparing the noninvasive oxygen saturation measurement (SpO2) of the pulse oximeter sensors to the arterial oxygen saturation (SaO2) value obtained from a reference blood sample and calculating the Accuracy root square mean (ARMS) value.

    Time frame: 1-5 hours

07

Results

Posted Oct 6, 2022

Participant flow

Participant flow — Overall Study
MilestoneINVSENSOR00039
Started38
Completed25
Not completed13
Withdrew: Did not proceed due to time constraints9
Withdrew: Screen failures4

Outcome measures

PrimaryOxygen Saturation (SpO2) Accuracy of Sensor

Performance of the sensors will be determined by comparing the noninvasive oxygen saturation measurement (SpO2) of the pulse oximeter sensors to the arterial oxygen saturation (SaO2) value obtained from a reference blood sample and calculating the Accuracy root square mean (ARMS) value.

Time frame:
1-5 hours
Reported as:
Number · percentage of oxygen saturation
Oxygen Saturation (SpO2) Accuracy of Sensor
percentage of oxygen saturationINVSENSOR00039
Oxygen Saturation (SpO2) Accuracy of Sensor1.0

Adverse events

Collected over 1 to 5 hours. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
INVSENSOR000390/25 (0%)0/25 (0%)0/25 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)INVSENSOR00039
<=18 years0
Between 18 and 65 years25
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)INVSENSOR00039
Female10
Male15
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)INVSENSOR00039
Asian or Pacific Islander4
Black/African American6
Caucasian10
Hispanic5
08

Study locations

1 site
  • Masimo Corporation
    Irvine, California 92618, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Aug 6, 2019

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04112784
Lead sponsor
Masimo Corporation
Responsible party
Sponsor
First posted
Oct 2, 2019
Start date
Sep 17, 2019
Primary completion
Oct 9, 2019
Completion
Oct 9, 2019
Results posted
Oct 6, 2022
Last update
Oct 6, 2022

Oversight

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion